A Randomized Study of XEN1101 Versus Placebo in Focal-Onset Seizures (X-TOLE3)
Trial details
- Registry ID
- NCT05716100
- Drugs studied
- XEN1101
TrialRedline tracks 13 clinical trials sponsored by Xenon Pharmaceuticals Inc.: 11 Phase 3, 2 Phase 2.
Company identity checked against sources
| Trial | Drugs studied | Status | Primary completion |
|---|---|---|---|
| A Study to Evaluate XEN1101 as Adjunctive Therapy in Focal EpilepsyNCT03796962 | XEN1101 | Active not recruiting | 2021-09-02Actual |
| A Study to Evaluate the Safety, Tolerability and Efficacy of XEN1101 in Major Depressive DisorderNCT05376150 | XEN1101 10 mg, XEN1101 20 mg | Completed | 2023-09-18Actual |
Names as written in the registry records.
NCT06775379 · Xenon Pharmaceuticals Inc.
Before: Estimated. After: Actual.
Before: 450 participants (planned). After: 357 participants (actual).
Before: Estimated. After: Actual.
Before: Oct 2026. After: 28 Oct 2026.
Before: Active not recruiting. After: Terminated.
NCT07076407 · Xenon Pharmaceuticals Inc.
Before: Recruiting. After: Active not recruiting.
NCT07172516 · Xenon Pharmaceuticals Inc.
Before: Recruiting. After: Active not recruiting.
NCT07217860 · Xenon Pharmaceuticals Inc.
Before: Enrolling by invitation. After: Active not recruiting.
NCT06922110 · Xenon Pharmaceuticals Inc.
Before: Enrolling by invitation. After: Active not recruiting.
NCT06775379 · Xenon Pharmaceuticals Inc.
Before: Aug 2026. After: Oct 2026.
Before: Recruiting. After: Active not recruiting.
NCT05716100 · Xenon Pharmaceuticals Inc.
Before: Oct 2026. After: Jan 2028.
NCT05376150 · Xenon Pharmaceuticals Inc.
Text changed; whether the study measures changed has not been verified. Saved text may be shortened.
Before: Measure: Change in Montgomery-Åsberg Depression Rating Scale (MADRS) score. Measure: Frequency and severity of treatment-emergent adverse events (TEAEs), treatment-emergent serious adverse events (SAEs), and TEAEs leading to treatment discontinuations.. After: Measure: Change in Montgomery-Åsberg Depression Rating Scale (MADRS) Score..
NCT05718817 · Xenon Pharmaceuticals Inc.
Before: Jul 2028. After: Apr 2033.
NCT05614063 · Xenon Pharmaceuticals Inc.
Before: Estimated. After: Actual.
Before: 360 participants (planned). After: 380 participants (actual).
Before: Estimated. After: Actual.
Before: Dec 2025. After: 12 Jan 2026.
Before: Active not recruiting. After: Completed.